Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 9/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | ESRRB | O95718 | 4/20 | 0.47 |
| ▸ | ESRRA | P11474 | 4/20 | 0.47 |
| ▸ | GRM5 | P41594 | 4/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3907064 | 0.80 | PARP1 (0.42) | ADORA1ADORA2AADORA2BESRRBESRRA | |
| SCHEMBL16645289 | 0.80 | RORC (0.48) | ADORA1ADORA2AADORA2BESRRBESRRA | |
| SCHEMBL3906128 | 0.79 | DPP4 (0.43) | ADORA1ADORA2AADORA2BESRRBESRRA | |
| SCHEMBL3901308 | 0.78 | DPP4 (0.44) | ADORA1ADORA2AADORA2BESRRBESRRA | |
| SCHEMBL3895581 | 0.77 | DPP4 (0.45) | ADORA1ADORA2AADORA2BESRRBESRRA | |
| SCHEMBL3895920 | 0.77 | ADORA1 (0.40) | ADORA1ADORA2AADORA2BESRRBESRRA | |
| SCHEMBL3893950 | 0.77 | ESRRB (0.41) | ADORA1ADORA2AADORA2BESRRBESRRA | |
| SCHEMBL3893249 | 0.76 | KDM4E (0.41) | ADORA1ADORA2AADORA2BESRRBESRRA | |
| SCHEMBL3896592 | 0.76 | DPP4 (0.46) | ADORA1ADORA2AADORA2BESRRBESRRA | |
| SCHEMBL3903116 | 0.76 | ESRRB (0.40) | ADORA1ADORA2AADORA2BESRRBESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547710-B2 | Fused heterocyclic compounds as peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-16 | — | — | US | disclosed |
| EP-1527049-B1 | FUSED HETEROCYCLIC COMPOUNDS AS PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20060135530-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135530-A1 | Fused heterocyclic compounds | NR4A3, DPP3, INSR | ADORA1 3265/4885ADORA2A 4256/4885ADORA2B 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.